Core Viewpoint - The internal audit management system of Shaanxi Panlong Pharmaceutical Group Co., Ltd. aims to enhance internal audit work, reduce decision-making risks, improve economic efficiency, and ensure healthy business operations in accordance with relevant laws and regulations [1][2]. Group 1: General Principles - The internal audit management system is established based on the Audit Law of the People's Republic of China and other regulatory guidelines to strengthen internal audit work [1]. - The audited entities include various departments, subsidiaries, and responsible personnel within the company [1]. Group 2: Organizational Structure and Responsibilities - The company has established an audit department as the internal audit body, responsible for supervising business activities, risk management, internal controls, and financial information [2]. - The audit department is independent and should not be under the leadership of the finance department [2]. - The audit department reports to the board of directors and is supervised by the audit committee [2]. Group 3: Scope and Authority - The audit department conducts audits on financial plans, cost plans, financial activities, major economic contracts, internal control systems, and compliance with financial regulations [4][5]. - The audit department has the authority to request necessary documents, attend relevant meetings, and propose temporary measures against violations of financial regulations [5]. Group 4: Audit Types and Methods - The main types of audits include financial audits and special audits focusing on the legality and effectiveness of economic activities [9]. - Audit methods include document review, observation, inquiry, and analytical review to gather sufficient and relevant evidence [6]. Group 5: Reporting and Evaluation - The audit department must report at least quarterly to the board or audit committee on the execution of the audit plan and any issues found [6]. - The audit committee oversees the audit department and ensures that internal control evaluations are conducted regularly [7][8]. Group 6: Confidentiality and Personnel - The audit department must maintain confidentiality and not disclose internal audit information to unauthorized parties [12]. - Audit personnel are required to possess necessary professional knowledge and adhere to ethical standards in their work [20][24].

陕西盘龙药业集团股份有限公司中小投资者单独计票机制实施细则 陕西盘龙药业集团股份有限公司 （2025 年 8 月） 第一章 总则 第一条 为进一步落实国家有关加强资本市场中小投资者合法权益保护工作 意见，充分保障中小投资者依法行使权利，完善公司股东会表决相关重大事项 时对中小投资者的投票情况进行单独计票的流程及披露机制，根据有关法律、 法规和规范性文件，结合陕西盘龙药业集团股份有限公司（以下简称"公司"） 实际情况，制定本细则。 （一）利润分配方案、资本公积金转增股本方案、弥补亏损方案； （二）修改公司章程中涉及中小投资者利益的条款； （三）发行公司证券； （四）重大资产重组； （五）公司合并、分立、解散、清算； （六）重大关联交易； （七）股权激励计划； （八）重大对外投资、对外担保、对外提供财务资助； （九）选举和更换非由职工代表担任的董事，决定有关董事、高级管理人 员的报酬事项； 第二条 本细则所称中小投资者是指股东会股权登记日除公司董事、高级管 理人员以及单独或者合计持有公司5%以上（含本数）股份的股东以外的其他股 东。 第二章 单独计票的适用范围 第三条 股东会审议影响中小投资者利益的重大事项时，对 ...

Core Viewpoint - The document outlines the information disclosure management system of Shaanxi Panlong Pharmaceutical Group Co., Ltd, emphasizing the importance of timely, accurate, and complete information disclosure to protect the rights of investors and comply with relevant laws and regulations. Group 1: General Principles - The company aims to ensure that all disclosed information is true, accurate, complete, timely, and fair, without any false records or misleading statements [3][4][5] - Information disclosure obligations apply to the company, its directors, senior management, and other relevant parties, ensuring that significant events affecting stock prices are disclosed promptly [2][6] Group 2: Disclosure Procedures - The company must disclose periodic reports, including annual and interim reports, which should be audited by qualified accounting firms [10][21] - The disclosure of significant events must occur immediately when they are known, especially if they could impact stock prices [18][22] Group 3: Responsibilities and Oversight - The board of directors is responsible for establishing and implementing the information disclosure management system, ensuring compliance and timely disclosures [15][19] - The audit committee and independent directors are tasked with supervising the implementation of the disclosure system and addressing any deficiencies [8][29] Group 4: Specific Disclosure Requirements - The company must disclose information regarding major shareholders, changes in control, and any significant legal proceedings that could affect its financial status [20][34] - Any changes in the company's financial performance or significant operational events must be reported to maintain transparency with investors [14][16]

General Principles - The company establishes a management system for the deferral and exemption of information disclosure to regulate the behavior of the company and other information disclosure obligors, enhance information disclosure supervision, and protect investors' legitimate rights and interests [1][2] - The company and other information disclosure obligors must disclose information truthfully, accurately, completely, timely, and fairly, and must not abuse deferral or exemption to evade disclosure obligations or mislead investors [1][2] Scope and Management of Deferral and Exemption - The company can exempt disclosure if there is sufficient evidence that the information involves state secrets or other matters that may violate state confidentiality regulations [2][3] - The company has an obligation to protect state secrets and must not leak them through any form of information disclosure or interaction with investors [2][3] - Information involving commercial secrets can be deferred or exempted if it meets certain conditions, such as being core technology information that could lead to unfair competition if disclosed [2][3] Internal Review Procedures - The company’s board secretary is responsible for organizing and coordinating the deferral and exemption of information disclosure, with the board office handling daily operations [5] - If a deferral or exemption application is not approved by the board secretary or the chairman, the company must disclose the information in accordance with securities regulatory requirements [5] Reporting and Documentation - The company must register details of the deferral or exemption, including the type of documents involved and the internal review procedures [4][5] - After the annual, semi-annual, or quarterly reports are announced, the company must submit relevant registration materials regarding deferrals or exemptions to the local securities regulatory bureau and stock exchange within ten days [4][5]

陕西盘龙药业集团股份有限公司累积投票制度实施细则 陕西盘龙药业集团股份有限公司 （2025 年 月） 第一章 总则 第一条 为进一步完善公司法人治理结构，规范公司董事的选举，保证股东 充分行使权利，维护中小投资者利益，根据《中华人民共和国公司法》、 《上市公 司治理准则》、 《深圳证券交易所股票上市规则》、 《深圳证券交易所上市公司自律 股东会主持人应在会上向出席会议股东明确说明以上注意事项，计票人员应 认真核对选票，以保证投票的公正、有效。 监管指引第 1 号—主板上市公司规范运作》及公司章程的有关规定，特制订本实 施细则。 第二条 本细则所指累积投票制，是指公司股东会选举董事时，出席股东会 的股东所拥有的投票权等于其所持有的股份总数乘以应选董事人数之积，出席会 议股东可以将其拥有的投票权全部投向一位董事候选人，也可以将其拥有的投票 权分散投向多位董事候选人，获选董事按应选董事人数依次以得票较高者确定。 股东会就选举董事进行表决时，实行累积投票制。 本细则所称的董事包括独立董事和非独立董事，不包括职工代表董事，由职 工代表担任的董事由公司职工民主选举产生或更换，不适用本实施细则的相关规 定。 第三条 为确保 ...

（2025 年 月） 陕西盘龙药业集团股份有限公司募集资金管理制度 陕西盘龙药业集团股份有限公司 第一章 总则 第一条 为规范陕西盘龙药业集团股份有限公司（以下简称"公司"）募集 资金管理，提高募集资金使用效率，根据《中华人民共和国公司法》、 《中华人民 共和国证券法》 （以下简称"证券法"）、 《首次公开发行股票注册管理办法》、 《深 《深圳证券交易所上市公司监管指引 1 号—主板上 圳证券交易所股票上市规则》、 市公司规范运作》《上市公司募集资金监管规则》、《陕西盘龙药业集团股份有限 公司章程》 （以下简称"公司章程"）以及其他有关法律、法规的规定，并结合公 司实际情况，制定本制度。 第二条 本管理制度所称募集资金是指公司通过向不特定对象发行证券（包 括首次公开发行股票、配股、增发、发行可转换公司债券、发行分离交易的可转 换公司债券、发行权证等）以及向特定对象发行股票向投资者募集并用于特定用 途的资金。 发行股票、可转换债券或其他证券的募集资金到位后，公司应及时办理验资 手续，由具有证券从业资格的会计师事务所出具验资报告。 第三条 公司董事会应当对募集资金投资项目的可行性进行充分论证，确信 投资项目具有较 ...

陕西盘龙药业集团股份有限公司 陕西盘龙药业集团股份有限公司 章程 二〇二五年 月 （以下简称"公司法"）、 《中华人民共和国证券法》 （以下简称"证 券法"）、 《上市公司证券发行注册管理办法（2025 年修订）》、 陕西盘龙药业集团股份有限公司 陕西盘龙药业集团股份有限公司 陕西盘龙药业集团股份有限公司 章程 第一章 总则 第一条 为维护陕西盘龙药业集团股份有限公司（以下简称"公司"）及 其股东、职工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共 和国公司法》 第七条 公司为永久存续的股份有限公司。 《上市公司章程指 引》、 《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》、 《中国共产党章程》和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关法律、行政法规设立的股份有 限公司。 公司采取发起设立的方式设立；在陕西省市场监督管理局注册登记，取得营 业执照，营业执照号为 91610000223472005U。 第三条 公司于 2017 年 10 月 20 日经中国证券监督管理委员会（以下简称 "中国证监会"）批准，首次向社会公众发行人民币普通股 2,167 ...

General Principles - The management system for online voting at the shareholders' meeting of Shaanxi Panlong Pharmaceutical Group Co., Ltd. is established to standardize online voting behavior, facilitate shareholders in exercising their voting rights, and protect investors' legal rights [2][3] - The online voting system includes the Shenzhen Stock Exchange trading system and an internet voting system [2][3] Voting Rights and Procedures - All shareholders registered on the equity registration date have the right to vote through the online voting system, and the same shares can only choose one voting method [3][4] - The company must provide a secure, economical, and convenient online voting system for shareholders during the shareholders' meeting [3][6] Preparation for Online Voting - The company must clearly state voting codes, proposal numbers, voting time, and other relevant information in the notice of the shareholders' meeting [5][6] - The company is required to complete the review of voting information by the trading day following the equity registration date [6][7] Voting Methods - Voting through the Shenzhen Stock Exchange trading system occurs during the trading hours of the shareholders' meeting [8][9] - The internet voting system is available from 9:15 AM on the day of the shareholders' meeting until 3:00 PM on the same day [10][11] Voting Results and Counting Rules - Shareholders who vote multiple times through the online voting system will be considered present at the meeting, and their votes will be counted based on the number of shares held [13][14] - The company must provide a voting platform that prioritizes online voting for significant matters affecting minority investors [14][15] Special Voting Provisions - For cumulative voting proposals, shareholders have voting rights equivalent to the number of candidates to be elected [17][18] - The company must ensure that votes from shareholders with special voting rights are counted according to the original voting data [21][22] Finalization of Voting Results - After the on-site voting concludes, the company will obtain online voting data and ensure compliance in confirming the voting results [24][25] - The company is responsible for the service fees associated with online voting [26][27]

证券代码：002864 证券简称：盘龙药业 公告编号：2025-030 陕西盘龙药业集团股份有限公司 第四届董事会第二十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 陕西盘龙药业集团股份有限公司（以下简称"公司"）第四届董事会第二十 五次会议通知于 2025 年 8 月 16 日以邮件方式向各位董事、独立董事发出。会议 于 2025 年 8 月 26 日上午 9:00 在西安市灞桥区现代纺织产业园灞柳二路 2801 号陕西盘龙医药股份有限公司二楼会议室召开，本次会议采用现场方式召开。会 议应出席董事 9 名，实际参加表决董事 9 名。会议由公司董事长谢晓林先生召集 并主持，公司监事及高级管理人员列席了本次会议。会议的召集和召开符合《中 华人民共和国公司法》等法律、行政法规、部门规章、规范性文件及《陕西盘龙 药业集团股份有限公司章程》的有关规定。 1 半年度募集资金存放与使用情况的专项报告》。 二、董事会会议审议情况 1. 审议通过了《关于<2025 年半年度报告>及其摘要的议案》 表决结果：同意票 9 票，反对票 0 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2025-036 陕西盘龙药业集团股份有限公司 关于 2025 年半年度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 陕西盘龙药业集团股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日 召开第四届董事会第二十五次会议、第四届监事会第二十一次会议，分别审议通 过了《关于 2025 年半年度利润分配方案的议案》，该项议案已获 2024 年年度股 东会授权。 若在方案实施前公司总股本由于可转债转股、股份回购、股权激励行权、再 融资新增股份上市等原因而发生变化的，按照分配总额不变，相应调整每股分配 比例，如后续总股本发生变化，将另行公告具体调整情况。 三、利润分配方案的合理性说明 公司董事会基于对公司未来发展的信心，增强投资者获得感，基于公司当前 实际经营、现金流状况、未来发展情况等因素作出的，不会对公司的经营活动现 1 金流产生重大影响，也不会影响公司正常经营和长期发展。 本次利润分配方案符合《公司法》《上市公司监管指引第 3 号——上市公司 现金分红》及《公司 ...